Detection and Possible Prognostic Relevance of p53 Gene Mutations in Diffuse Large B-cell Lymphoma. An Analysis of 51 Cases and Review of the Literature

References

• Molina, A. and Pezner, R.D. (1999) Cancer management: a multidisciplinary approach. In Non-Hodgkin's lymphoma, edited by Richard Pazdur, Lawrence R. Coia, William J. Hoskins, Lawrence D. Wagman. Pp 525— 558. Mellvine, NY: PPR.
   Google Scholar
• Barrans, S.L., Carter, I., Owen, R.G., Davies, F.E., Patmore, R.D., Haynes, A.P., et al. (2002) "Germinal center phenotype and bc1-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lympho-ma", Blood, 99, 1136 — 1143.
   Google Scholar
• Cheson, B.D. (2002) "CHOP plus Rituximab-balancing facts and opinion", New England Journal of Medicine, 346, 280 — 282.
   PubMed Web of Science ®Google Scholar
• Shipp, M.A., Harrington, D.P., Anderson, J.R., Armitage, J.O., Bonadonna, G., Brittinger, G., et al. (1993) "A predictive model for aggressive NHL: The International Non-Hodgkin's Lymphoma Prognostic Factors Project", New England Journal of Medicine, 329, 987 — 994.
   PubMed Web of Science ®Google Scholar
• Hannun, Y.A. (1997) "Apoptosis and the dilemma of cancer chemotherapy", Blood, 89, 1845–1853.
   Google Scholar
• Soussi, T. and Beroud, C. (2001) "Assessing TP53 status in human tumors to evaluate clinical outcome", Cancer, 1, 233–240.
   PubMed Web of Science ®Google Scholar
• Soussi, T., Legros, Y., Lubin, R., Ory, K. and Schlichtholz, B. (1994) "Multifactorial analysis of p53 alteration in human cancer: a review", International Journal of Cancer, 57, 1–9.
   PubMed Web of Science ®Google Scholar
• Cho, Y., Gonna, S., Jeffrey, P.D. and Pavletich, N.P. (1994) "Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations", Science, 265, 346— 535.
   Google Scholar
• Zhao, K., Chai, X., Johnston, K., Clements, A. and Marmorstein, R. (2001) "Crystal structure of the mouse p53 core DNA-binding domain at 2.7 A resolution", Journal of Biology and Chemistry, 276, 12120–12127.
   PubMed Web of Science ®Google Scholar
• Pins, M.A., Pezzella, F., Martinez-Montero, J.C., Orradre, J.L., Villuendas, R., Sanchez-Beato, M., et al. (1994) "P53 and Bc1-2 expression in high-grade B-cell lymphomas: correlation with survival time", British Journal of Cancer, 69, 337–341.
   PubMed Web of Science ®Google Scholar
• Ichikawa, A., Kinoshita, T., Watanabe, T., Kato, H., Nagai, H., Tsushita, K., et al. (1997) "Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma", New England Journal of Medicine, 337, 529–534.
   PubMed Web of Science ®Google Scholar
• Koduru, P.R., Raju, K., Vadmal, V., Menezes, G., Shah, S., Susin, M., et al. (1997) "Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma", Blood, 90, 4078–4091.
   PubMed Web of Science ®Google Scholar
• Moller, M.B., Ino, Y., Gerdes, A.-M., Skjodt, K., Louis, D.N. and Pedersen, N.T. (1999) "Aberrations of the p53 pathway components p53, mdm2 and CDKN2A appear independent in diffuse large cell lymphoma", Leukemia, 13, 453 —459.
   Google Scholar
• Sanchez-Beato, M., Saez, Al., Navas, IC., Algara, P., Sol Mateo, M., Villuendas, R., et al. (2001) "Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27", American Journal of Pathology, 159, 205 — 213.
   Google Scholar
• Kramer, M.H., Hermans, J., Parker, J., Krol, A.D., Kluin-Nelemans, J.C., Haak, H.L., et al. (1996) "Clinical significance of bc1-2 and p53 protein expression in difuse large B-cell lymphoma: a population-based study", Journal of Clinical Oncology, 14, 2131 — 2138.
   Web of Science ®Google Scholar
• Osada, M., Ishioka, C., Ichinohasama, R., Kadowalci, I., Mur-akawa, Y., Watanabe, M., et al. (1999) "Influence of p53 mutation on pathological grade but not prognosis in non-Hodgkin's lymphoma", Anticancer Drug Research, 14, 107 — 114.
   Google Scholar
• Leroy, K., Haioun, C., Lepage, E., Le Metayer, N., Berger, F., Labouyrie, E., et al. (2002) "p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas", Annals of Oncology, 13, 1108–1115.
   PubMed Web of Science ®Google Scholar
• NCCN. National Comprehensive Cancer Network. The complete library of practice guidelines in oncology. Version 2001 (www.nccn.org)
   Google Scholar
• Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, RI., Connors, J.M., et al. (1999) "Report of international workshop to standardize response criteria for non-Hodgkin's lymphomas", Journal of Clinical Oncology, 17, 1244 — 1253.
   Web of Science ®Google Scholar
• Harris, N.L., Jaffe, ES., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., et al. (1999) "World Health Organization of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meet-ing-Airlie House, Virginia, November 1997", Journal of Clinical Oncology, 17, 3835–3849.
   PubMed Web of Science ®Google Scholar
• Seidman, J.G. (1997) In situ hybridization and immunohistochem-istry. In Short Protocols in Molecular Biology, edited by F. Ausbel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith and K. Sthruhl. Pp 14.22-26. New York: John Wiley Sons Inc.
   Google Scholar
• Sanchez-Aguilera, A., Sanchez-Beato, M., Garcia, J.F., Prieto, I., Pollan, M. and Piris, M.A. (2002) "p14aARF nuclear over-expression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways", Blood, 99, 1411–1418.
   PubMed Web of Science ®Google Scholar
• Volkenandt, M., Dicker, A.P. and Fanin, R. (1993) Polymerase chain reaction analysis of DNA from paraffin-embedded Tissue. In PCR Protocols — Current Methods and Applications, edited by B.A. White. Pp 75–81. Totowa, NJ: Humana Press Inc.
   Google Scholar
• Lee, T.H., Sakahara, N.S., Fiebig, E.W., Hirschkorn, D.F., Johnson, D.K. and Busch, M.P. (1998) "Quantitation of white cell subpopulations by polymerase chain reaction using frozen whole-blood samples", Transfusion, 38, 262–270.
   Google Scholar
• Chilosi, M., Doglioni, C., Magalini, A., Inghirami, G., Krampera, M., Nadali, G., et al. (1996) "p21/WAF1 cyclin-lcinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function", Blood, 88, 4012–4020.
   Google Scholar
• Oliver, M., Eeles, R., Hollstein, M., Khan, M.A., Harris, C.C. and Hainaut, P. (2002) "The IARC TP53 Database: new on line mutation analysis and recommendations to users", Human Muta-tion, 19, 607–614.
   PubMed Web of Science ®Google Scholar
• Kaplan, E.L. and Meier, P. (1958) "Non-parametric estimation from incomplete observations", Journal of American Statistics Association, 53, 457–481.
   Web of Science ®Google Scholar
• Cox, D.R. (1972) "Regression models and life tables", Journal of Statistics Society (B), 34, 187–202.
   Web of Science ®Google Scholar
• Shipp, M.A., Abeloff, M.D., Antman, K.H., Carrol, G., Hagen-beck, A., Loeffler, M., et al. (1999) "International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive NHL: report of the jury", Journal of Clinical Oncology, 17, 423–429.
   PubMed Web of Science ®Google Scholar
• Rosenwald, A., Wrigh, G., Chan, W., Connors, J.M., Campo, E., Fisher, R., et al. (2002) "The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma", New England Journal of Medicine, 346, 1937–1947.
   Web of Science ®Google Scholar
• Levine, A.M., Scadden, D.T., Zaia, J.A. and Krishnan, A. (2001) "Hematologic aspects of HIV/AIDS", Hematology (Am. Soc. Hematol. Educ. Program), 463–478.
   PubMedGoogle Scholar
• Spina, M., Carbone, A., Vaccher, E., Gloghini, A., Talamini, R., Cinelli, R., et al. (2003) "Outcome in patients with non-hodglcin lymphoma and with or without human immunodeficiency virus infection", Clinical of Infection Disease, 38, 142 — 144.
   Google Scholar
• Villluendas, R., Pezzella, F., Gatter, K., Algara, P., Sánchez-Beato, M., Martinez, P., et al. (1997) "p21WAF1/CIP1 and mdm2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: A p53 +, mdm2-, p21- immunophenotype associated with missense p53 mutations", Journal of Pathology, 181, 51–61.
   Web of Science ®Google Scholar
• Maestro, R., Gloghini, A., Doglioni, C., Piccinin, S., Vukosavljevic, T., Gasparotto, D., et al. (1997) "Human non-Hodgkin's lympho-mas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent lcinase inhibitor p21", Blood, 98, 2523–2528.
   PubMed Web of Science ®Google Scholar
• Moller, M.B., Gerdes, A.M., Skjodt, K., Mortensen, L.S. and Pedersen, N.T. (1999) "Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma", Clinical Cancer Research, 5, 1085–1091.
   PubMed Web of Science ®Google Scholar
• Wilson, W.H., Teruya-Feldstein, J., Fest, T., Harris, C., Steinberg, S.M., Jaffe, ES., et al. (1997) "Relationship of p53, bc1-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas", Blood, 89, 601 — 609.
   Google Scholar
• Unger, T., Nau, M.M., Segal, S. and Minna, J.D. (1992) "p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer", Journal of European Molecular Biology Organization, 11, 1383— 1390.
   Google Scholar